Publications by authors named "James C Gilbert"

Claim this Profile
T
The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1.
Alain Chion, Ciara Byrne, Ferdows Atiq, Dearbhla Doherty, Sonia Aguila, James C Gilbert

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans.
Min-Soo Kim, Dagmar M Hajducek, James C Gilbert, Alfonso Iorio, Bernd Jilma

AAPS J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A.
Cihan Ay, Katarina D Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, James C Gilbert

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial.
Katarina D Kovacevic, Jürgen Grafeneder, Christian Schörgenhofer, Georg Gelbenegger, Gloria Gager, James C Gilbert

Haematologica· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.
Cihan Ay, Ingrid Pabinger, Katarina D Kovacevic, Georg Gelbenegger, Christian Schörgenhofer, James C Gilbert

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.
Katarina D Kovacevic, Stefan Greisenegger, Agnes Langer, Georg Gelbenegger, Nina Buchtele, James C Gilbert

Sci Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo.
Katarina D Kovacevic, Bernd Jilma, Shuhao Zhu, James C Gilbert, Max-Paul Winter

Thromb Haemost· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200.
Shuhao Zhu, James C Gilbert, Zicai Liang, Daiwu Kang, Ming Li

J Thromb Haemost· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.
Katarina D Kovacevic, Nina Buchtele, Christian Schoergenhofer, Ulla Derhaschnig, Georg Gelbenegger, James C Gilbert

Sci Rep· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer.
Shuhao Zhu, James C Gilbert, Paul Hatala, Warren Harvey, Zicai Liang

J Thromb Haemost· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
Georg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, Nina Buchtele, Christian Sillaber, James C Gilbert

Blood Adv· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid.
Patricia Colchete Freire, Cristina Herraez Muñoz, Ulla Derhaschnig, Christian Schoergenhofer, Christa Firbas, James C Gilbert

J Invest Dermatol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Ulrich Jäger, Shirley D'Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, James C Gilbert

Blood· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.
Johann Bartko, Christian Schoergenhofer, Michael Schwameis, Christa Firbas, Martin Beliveau, James C Gilbert

Clin Pharmacol Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics and safety of aptamers.
Katarina D Kovacevic, James C Gilbert, Bernd Jilma

Adv Drug Deliv Rev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.
Nina Buchtele, Michael Schwameis, James C Gilbert, Christian Schörgenhofer, Bernd Jilma

Thromb Haemost· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.
Jakob Mühlbacher, Bernd Jilma, Markus Wahrmann, Johann Bartko, Farsad Eskandary, James C Gilbert

Transplantation· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
Leonid A Parunov, Natalia P Soshitova, Olga A Fadeeva, Anna N Balandina, Konstantin G Kopylov, James C Gilbert

Thromb Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis.
Dabit Arzamendi, Firas Dandachli, Jean-François Théorêt, Gregory Ducrocq, Mark Chan, James C Gilbert

Clin Appl Thromb Hemost· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Petra Jilma-Stohlawetz, Paul Knöbl, James C Gilbert, Bernd Jilma

Thromb Haemost· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.
Spero R Cataland, Flora Peyvandi, Pier M Mannucci, Bernhard Lämmle, Johanna A Kremer Hovinga, James C Gilbert

Am J Hematol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Petra Jilma-Stohlawetz, James C Gilbert, Monika E Gorczyca, Paul Knöbl, Bernd Jilma

Thromb Haemost· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
Petra Jilma-Stohlawetz, Monika E Gorczyca, Bernd Jilma, Jolanta Siller-Matula, James C Gilbert

Thromb Haemost· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.
Spero R Cataland, Marie A Scully, James Paskavitz, Paul Maruff, Leslie Witkoff, James C Gilbert

Am J Hematol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the practice for pediatric surgery--career satisfaction and concerns. A report from the American Pediatric Surgical Association Task Force on Family Issues.
Aviva Katz, Baird Mallory, James C Gilbert, Colin Bethel, Andrea A Hayes-Jordan

J Pediatr Surg· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis